Exhibit 107

Calculation of Filing Fee Tables

F-1

(Form Type)

QUOIN PHARMACEUTICALS LTD.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

Filing Fee

Previously

Paid in

Connection

with

Fee

Proposed

Carry

Unsold

Calculation

Maximum

Carry

Forward

Securities

or Carry

Offering

Maximum

Amount of

Forward

Initial

to be

Security

Forward

Amount

Price Per

Aggregate

Registration

Form

File

Effective

Carried

Type

Class Title⁽¹⁾

Rule

Registered

Unit

Offering Price

Fee Rate

Fee

Type

Number

Date

Forward

Newly Registered Securities

Fees to be Paid

Equity

Ordinary

shares,

no par value

per share,

underlying

American

Depositary

Shares,

issuable upon

the exercise of

the Warrants

457

(c)

6,435,548,000⁽²⁾⁽³⁾

0.0029⁽⁴⁾

18,663,089.20

0.0000927

1,730.07

Fees Previously Paid

Carry Forward Securities

Total Offering Amounts

Total Fees Previously Paid

Total Fees Offsets

Net Fee Due

(1)

American Depositary Shares (“ADSs”) issuable upon deposit of ordinary shares registered hereby have been registered under a separate registration statement on Form F-6 (Registration No. 333-212698) filed with the Securities and Exchange Commission. Each ADS represents four hundred (400) A ordinary shares.

(2)

Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), there are also being registered such additional ordinary shares that may be issued because of events such as recapitalizations, stock dividends, stock splits and reverse stock splits, and similar transactions.

(3)

We are registering for resale by the selling shareholders named in the Registration Statement on Form F-1 ordinary shares represented by ADSs issuable upon the exercise of the Warrants, assuming the Warrants are exercised in full.

(4)

Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) under the Securities Act, based upon the average of the high and low prices per ADS on April 11, 2022, a date within five business days prior to the filing of this registration statement, as reported on the Nasdaq Capital Market, and adjusted to reflect the ADS ratio of 400 ordinary shares per ADS.